Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Carnival CEO Comments on the Current State of the Cruise Industry

Carnival Corp. Chief Executive Officer Arnold Donald expressed optimism for recovery in the cruise industry, citing pent-up demand from regular cruisers. Donald spoke with Bloomberg’s Ed Hammond about these topics and more. Watch or read the transcript below. — Donald: We [Carnival] have a nice liquidity runway, we’re at the point where we still have…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Carnival CEO Comments on the Current State of the Cruise Industry

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Carnival Corp. Chief Executive Officer Arnold Donald expressed optimism for recovery in the cruise industry, citing pent-up demand from regular cruisers. Donald spoke with Bloomberg’s Ed Hammond about these topics and more. Watch or read the transcript below.

Donald: We [Carnival] have a nice liquidity runway, we’re at the point where we still have additional debt, we could secure if we needed it, and obviously, we will be opportunistic with regards to the balance sheet overall and in terms of equity. And so on. But at this point, we have the liquidity.

We need, you know, for to take us well into next year. And so with zero revenue. And obviously, we’re hoping to have some revenue this year and the beginning, it was a tough time.

You know, some of the debt we raise were at rates, you know, that we never would have even considered in the past. Then even more recent ones are at rates where we’re happy about them now. But, you know, two years ago, we wouldn’t have been happy with those rates.

So it is what it is. But, you know, we’ll adapt. And we have a great resilient business, a great resilient industry.

We will be able to generate lots of cash. And over time, we’ll get back to the solid credit rating that we had prior to the pandemic.

Host: I’m interested in that resilience that you mentioned on, because if I look at this industry, I mean, look, every industry has suffered through COVID. But I think when I think about the cruise industry, there have been some real and very visceral horror stories that have gone on over the last year. I understand you have a sticky customer base, but how do you pitch this as a model to new potential cruises?

Donald: As we look ahead, we have over eight million repeat cruises in our world. And of carnival and our nine world brands. And there’s pent up demand, a cruise on average once every two years.

And so there’s a whole year of repeat cruises basically that haven’t been able to cruise. And so we have plenty of pent up demand. Additionally, we reduced the size of the fleet because obviously, we had ships that were less efficient, and it didn’t make sense when they weren’t generating revenue to continue to invest in those ships.

That’s one way we got our burn rate down. And so we plan to exit 19 ships. So that takes our capacity down when we do come back.

Furthermore, it’s going to be a staggered return. All the destinations aren’t going to open up at once. Different destinations will open at different times.

And so there will be plenty of pent up demand, as is evidenced by the bookings already. As you look at late 2021 and first half, second half of 2022, where the bookings are stronger than they were even prior to COVID on the same basis.

Host: But also, if the cruise from what I understand, this is right, if the cruise of the near future is sort of more people, you know, on these boats in sort of isolation from one another and lose something of its essence, I mean, isn’t the whole allure of going on a cruise that you get these you know, you get to jostle and mingle with strangers, you have this sort of conviviality by the waves. If you don’t have that, then do people really want to go cruising?

Donald: Look, first of all, you’re absolutely right that travel and cruising in particular is about people connecting with other people. What people remember are other people on the cruise ships. The ships are fabulous. We have lots of features, but it’s all about the human spirit and human exchange. And people learn what they have in common. And then they learn to celebrate the differences rather than fear them. And that’s whether it’s through the guests to guests, or guests to the locals of the various destinations that they visit. So you’re absolutely right about that. Having said that, we are ready to resume cruising in Italy and with our Constitution and in Germany on a very limited basis. But our net promoter scores and basically our guest satisfaction scores went through the roof. People love the experience.

*Bloomberg contributed to this content

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raised CAD $4.24 million in a pre-seed round, according to Fierce Healthcare. It plans to expand protocol-driven virtual specialty care across Canada and the U.S.

  • 01Blair Health raised CAD $4.24 million in pre-seed funding.
  • 02Qualified Health positions its AI platform around safety and governance, including clinician oversight, auditability and traceability, according to Fierce Healthcare.

Sep 23, 2026

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512